Nutritional Products International (NPI) would like to congratulate Dr. Joseph Purita and Reid Eckert on being named health ambassadors for Enzymedica, one of the world’s most renowned nutrition companies.
In their roles, Purita and Eckert will serve as medical and nutritional advisors to the company’s Enzymedica and Enzyme Science brands, helping to guide the education and scientific supervision of research and development activities. They join the organization at a time when its team is working on a number of new technologies related to the nutrition industry.
“Enzymedica is a major player in the nutrition industry, and we are thrilled and very proud that Joe and Reid have been appointed to this position,” said Mitch Gould, CEO of NPI and InHealth Media. “This is a company that is doing some groundbreaking things when it comes to nutritional and enzyme-related research, and we are happy to be a part of it.”
Dr. Purita, who serves on the NPI board of directors, also runs The Institute of Regenerative and Molecular Orthopedics in Boca Raton and has practiced at the Boca Raton Orthopaedic Group since 1981. He is a pioneer in both research and technology related to using stem cells and platelet-rich plasma therapy (PRP) as a complement or alternative to surgery. Dr. Purita received his medical degree from Georgetown University and throughout his career his innovations have helped treat professional athletes in the NFL, Major League Baseball and more.
Eckert, a certified nutritional counselor who is a medical advisor for InHealth Media, has helped a countless number of clients improve their nutrition and quality of life. He is the owner of the Nutrition Direct store in the Fort Lauderdale area, and has extensive knowledge and background in how vitamins, minerals, herbs and food supplements address the seven main systems of the body.
“These are two medical professionals who have provided both NPI and InHealth Media with valuable guidance and advice as we’ve moved forward, and I know they’ll do the same with this new venture,” said Gould.